Alar Pharmaceuticals Inc. (昱展新藥生技股份有限公司)

Company Overview

Alar Pharmaceuticals Inc. is a biotech company focused on developing long-acting drugs for Central Nervous System (CNS) diseases. The company was established in 2016 and is headquartered in the Central Taiwan Science Park.

Key Information

• CEO/General Manager: Dr. Wen Yong-Shun (文永順 博士)
• Date of Presentation: June, 2024
• Paid-in Capital: NTD 668,000 thousand
• R&D Center: Located in Phase II Standard Factory Building, Central Taiwan Science Park
• Main Development Projects: Long-acting drugs for Central Nervous System (CNS) diseases

Company Milestones

• 2016: Company established
• 2017: Approved by MOEA A+ Forward-looking Program (ALA-1000)
• 2019:
  • Settled in Central Taiwan Science Park
  • Certified as a Biotech New Drug Company
• 2020:
  • Approved by MOEA A+ Fast Track Clinical Program (ALA-1000)
  • Approved as a public company (stock code 6785) and listed on Taiwan's Emerging Stock Market
• 2021: Completed ALA-1000 US Phase I Clinical Trial
• 2022: Obtained approval letter for technology enterprise
• 2023: ALA-1000 and related products licensed to international major manufacturer Indivior
• 2024: Listed on Taiwan's OTC market (2024/01/24)

Products, Services & Technology

In-Relar Technology Platform

• Unique Sustained Release Mechanism:
  • Drug self-assembles in the subcutaneous space
  • Forms a complete, non-dispersing depot
  • Drug is steadily released from the depot
  • In-Relar provides a smoother release profile with less drug fluctuation compared to other long-acting platforms
• Features:
  • Low viscosity, biodegradable
  • Good stability (can be stored at room temperature)
  • Small injection volume (high drug loading)
  • Injection with very fine needles (26G or 30G)
  • Low local irritation
  • Can sustain release for 3-6 months
  • Needle sizes: 26G (for ALA-1000), 19G (for competitor products)

R&D Product Pipeline

Note: The R&D product pipeline table is not fully populated as the provided information only mentions ALA-1000. Additional products and their respective details are not included in the original text.